Life Science Product News

Researchers at the Fred Hutchinson Cancer Research Center use Droplet Digital PCR to quantify tumor-attacking immune cells (TILs) in cancer tissues in a promising effort to develop the use of TILs in immunotherapy and as a cancer survival predictor.

CFX Manager Version 3.1 software has new features for allelic discrimination and full integration with PrimePCR™ assays. The secure edition supports 21 CFR Part 11 compliance and is now compatible with all Bio-Rad CFX real-time PCR systems including the CFX96 Touch™ and CFX384 Touch™ systems.

New kits enable handcast gel users to access the benefits of Bio-Rad’s TGX gel chemistry, previously available only in precast gels: fast run times, efficient protein transfers, and long shelf life.

New copy number variation (CNV) studies using Droplet Digital PCR assays for more accurate, precise, and cost-effective CNV determination may lead to improved diagnosis and therapy for cancer and other diseases, including autoimmune disorders.

Scientists using Bio-Rad Droplet Digital PCR (ddPCR™) systems will present original ddPCR research applications at the Digital PCR Conference in San Diego, CA, Oct. 7–9. These applications have resulted in nearly 50 peer-reviewed publications in the last two years.

The new ddPCR™ library quantification kit for Ion Torrent NGS libraries is designed for use with Bio-Rad’s QX200™ Droplet Digital™ PCR system. The new kit provides researchers with the ability to precisely and directly measure amplifiable library concentrations.

Researchers at Fred Hutchinson Cancer Research Center have developed a new Droplet Digital PCR assay to accurately analyze extremely rare mitochondrial DNA (mtDNA) deletions associated with both aging and disease states.

A new study reports that Droplet Digital PCR (ddPCR™) technology can be used to precisely and reproducibly quantify microRNA (miRNA) in plasma and serum, enabling the use of miRNA and other nucleic acids as reliable blood-based disease biomarkers.

The researchers applied Bio-Rad’s ddPCR™ technology to quantify graft-derived cfDNA in recent liver transplant patients, making it a promising biomarker for early detection of rejection, potentially enabling more timely therapeutic intervention.

New iTaq universal one-step kits combine RNase H+ iScript reverse transcriptase and antibody-mediated hot-start iTaq DNA polymerase in one reaction for superior data precision and highly efficient reverse transcription quantitative PCR (RT-qPCR) performance under most reaction conditions on any qPCR instrument.